| Date | Title | | | 11/20/12 | MannKind Corporation to Present at The 24th Annual Piper Jaffray Healthcare Conference| VALENCIA, Calif.--(BUSINESS WIRE)--Nov. 20, 2012--
MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing
and commercializing treatments for diabetes and cancer, announced today
that it will present at The 24th Annual Piper Jaffray
Healthcare Conference on Tuesday, November 27, 2012 at 1:00 PM (EST) at
The New York Palace in New York.
Interested parties can access a link to the live webcast of the
presentations from th... |
|  | | 11/13/12 | Colby and MannKind Sign License and Joint Development Agreement to Develop and Commercialize Cancer Immunotherapy Products| SAN JOSE, Calif. & VALENCIA, Calif.--(BUSINESS WIRE)--Nov. 13, 2012--
Colby Pharmaceutical Company and MannKind Corporation (Nasdaq: MNKD)
today announced a license agreement granting Colby exclusive worldwide
rights to develop and commercialize disease-specific antigen compounds
and intra-lymph node delivery technologies from MannKind’s novel MKC1106
active immunotherapy programs, which are currently being developed for
the treatment of melanoma... |
| | | 11/01/12 | MannKind Corporation Reports 2012 Third Quarter Financial Results|
- Conference Call to Begin Today at 6:00 P.M. ET -
VALENCIA, Calif.--(BUSINESS WIRE)--Nov. 1, 2012--
MannKind Corporation (Nasdaq: MNKD) today reported financial
results for the third quarter ended September 30, 2012.
For the third quarter of 2012, total operating expenses were $35.5
million compared to $32.8 million for the third quarter of 2011, an
increase of $2.7 million. Research and development (R&D) expenses were
$25... |
| | | 10/29/12 | MannKind Corporation Reschedules 2012 Third Quarter Financial Results Conference Call to November 1, 2012 Due to Hurricane Sandy| VALENCIA, Calif.--(BUSINESS WIRE)--Oct. 29, 2012--
MannKind Corporation (Nasdaq: MNKD) today announced that, due to
the inclement weather associated with Hurricane Sandy, the Company has
rescheduled its release of 2012 third quarter financial results to
Thursday, November 1, 2012 after the close of regular trading. Following
the release, management will host a conference call to discuss the third
quarter financial results and other Company developmen... |
| | | 10/22/12 | MannKind Corporation to Hold 2012 Third Quarter Financial Results Conference Call on October 29, 2012| VALENCIA, Calif.--(BUSINESS WIRE)--Oct. 22, 2012--
MannKind Corporation (Nasdaq: MNKD) will release its 2012 third
quarter financial results on Monday, October 29, 2012 and its management
will host a conference call to discuss the third quarter financial
results and other Company developments at 5:00 PM (Eastern Time) on
October 29, 2012.
Presenting from the Company will be its Chairman and Chief Executive
Officer, Alfred Mann, Preside... |
| | | 10/18/12 | MannKind Announces Pricing of Public Offering of Common Stock and
Warrants| VALENCIA, Calif., Oct 18, 2012 (BUSINESS WIRE) --MannKind Corporation (Nasdaq: MNKD) today announced the pricing
of an underwritten public offering of 40,000,000 shares of its common
stock, together with warrants to purchase up to an aggregate of
30,000,000 shares of its common stock. Each share of common stock is
being sold together with a warrant for a combined purchase price of
$2.00. Each warrant entitles the holder to purchase 0.75 of a share of
... |
| | | 10/18/12 | MannKind Receives Commitment from The Mann Group to Acquire 40,000,000 Shares of Common Stock and Warrants to Purchase Common Stock| VALENCIA, Calif.--(BUSINESS WIRE)--Oct. 18, 2012--
MannKind Corporation (Nasdaq: MNKD) today announced that it has
entered into a purchase agreement with The Mann Group LLC, an entity
controlled by MannKind’s chief executive officer and principal
stockholder, Alfred E. Mann, for the sale of shares of its common stock
and warrants to purchase its common stock to The Mann Group. The Mann
Group has committed to purchase 40,000,000 restricted shares of
... |
| | | 10/17/12 | MannKind Announces Proposed Public Offering of Common Stock and Warrants| VALENCIA, Calif.--(BUSINESS WIRE)--Oct. 17, 2012--
MannKind Corporation (Nasdaq: MNKD) today announced that it
intends to offer and sell, subject to market and other conditions,
shares of its common stock and warrants to purchase shares of its common
stock in an underwritten public offering. There can be no assurance as
to whether or when the offering may be completed, or as to the actual
size or terms of the offering.
Jefferies & ... |
| | | 10/05/12 | MannKind Completes Patient Recruitment in Two Phase 3 Clinical Studies of AFREZZA| VALENCIA, Calif.--(BUSINESS WIRE)--Oct. 5, 2012--
MannKind Corporation (Nasdaq: MNKD) today announced that it has
completed recruiting patients for two Phase 3 clinical studies of AFREZZA®
(insulin human [rDNA origin]), an investigational, ultra rapid-acting
mealtime insulin therapy, administered using MannKind’s to-be-marketed
next-generation inhaler.
The first of these studies (study 171) is an open-label study in
patients with type ... |
| | | 09/04/12 | MannKind Corporation to Present at Upcoming Conferences| VALENCIA, Calif.--(BUSINESS WIRE)--Sep. 4, 2012--
MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing
and commercializing treatments for diabetes and cancer, announced today
that it will present at upcoming conferences.
Rodman & Renshaw Annual Global Investment Conference on Monday,
September 10, 2012 at 10:25 AM (ET) at the Waldorf-Astoria, New York
City.
Morgan Stanley Global He... |
| | | 08/07/12 | MannKind Corporation Reports 2012 Second Quarter Financial Results|
- Conference Call to Begin Today at 9:00 AM EDT -
VALENCIA, Calif.--(BUSINESS WIRE)--Aug. 7, 2012--
MannKind Corporation (Nasdaq: MNKD) today reported financial
results for the second quarter ended June 30, 2012.
For the second quarter of 2012, total operating expenses were $44.1
million, compared to $39.2 million for the second quarter of 2011, an
increase of $4.9 million. Research and development (R&D) expenses were
$26.6... |
| | | 07/31/12 | MannKind Corporation to Hold 2012 Second Quarter Financial Results Conference Call on August 7, 2012| VALENCIA, Calif.--(BUSINESS WIRE)--Jul. 31, 2012--
MannKind Corporation (Nasdaq: MNKD) will release its 2012 second
quarter financial results on Tuesday, August 7, 2012 and its management
will host a conference call to discuss the second quarter financial
results and other Company developments at 9:00 AM (Eastern Time) on
August 7, 2012.
Presenting from the Company will be its Chairman and Chief Executive
Officer, Alfred Mann, Presiden... |
| | | 07/05/12 | MannKind Corporation to Present at JMP Securities 7th Annual Healthcare Conference| VALENCIA, Calif.--(BUSINESS WIRE)--Jul. 5, 2012--
MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing
and commercializing treatments for diabetes and cancer, announced today
that it will present at the JMP Securities 7th Annual Healthcare
Conference on Thursday, July 12, 2012 at 2:30 PM (ET) at The Peninsula
Hotel in New York.
Interested parties can access a link to the live webcast of the
presentations from the New... |
| | | 06/12/12 | MannKind to Present at 2012 Wells Fargo Securities Healthcare Conference| VALENCIA, Calif.--(BUSINESS WIRE)--Jun. 12, 2012--
MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing
and commercializing treatments for diabetes and cancer, announced today
that it will present at the 2012 Wells Fargo Securities Healthcare
Conference on Tuesday, June 19, 2012 at 3:00 PM (ET) at the
InterContinental Hotel in Boston.
Interested parties can access a link to the live webcast of the
presentations from ... |
| | | 05/31/12 | MannKind to Present at Jefferies 2012 Global Healthcare Conference| VALENCIA, Calif.--(BUSINESS WIRE)--May. 31, 2012--
MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing
and commercializing treatments for diabetes and cancer, announced today
that it will present at the Jefferies 2012 Global Healthcare Conference
on Wednesday, June 6, 2012 at 11:30 AM (ET) in New York.
Interested parties can access a link to the live webcast of the
presentations from the News & Events section of the Co... |
| | | 05/31/12 | Pre-Clinical Data Demonstrates Promising Potential of MannKind’s IRE1α Inhibitor to Treat Multiple Myeloma|
Results published in the advance online edition of Blood show
blocking key pathway with MKC-3946 inhibited growth in multiple myeloma
cells
VALENCIA, Calif.--(BUSINESS WIRE)--May. 31, 2012--
Results published in Blood, the official journal of the American
Society of Hematology, confirm that inhibition of the IRE1α-XBP1 pathway
impacts the survival of myeloma cells, suggesting a promising
therapeutic option in multiple myeloma. The pre-... |
| | | 05/09/12 | MannKind Corporation Reports 2012 First Quarter Financial Results|
- Conference Call to Begin Today at 5:00 PM EDT -
VALENCIA, Calif.--(BUSINESS WIRE)--May. 9, 2012--
MannKind Corporation (Nasdaq: MNKD) today reported financial
results for the first quarter ended March 31, 2012.
For the first quarter of 2012, total operating expenses were $33.9
million, compared to $38.1 million for the first quarter of 2011, a
decrease of $4.1 million. Research and development (R&D) expenses were
... |
| | | 05/08/12 | MannKind to Present at Bank of America Merrill Lynch 2012 Health Care Conference| VALENCIA, Calif.--(BUSINESS WIRE)--May. 8, 2012--
MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing
and commercializing treatments for diabetes and cancer, announced today
that it will present at the Bank of America Merrill Lynch 2012 Health
Care Conference on Tuesday, May 15, 2012 at 10:40 am Pacific Daylight
Time at the Encore at the Wynn in Las Vegas, Nevada.
Interested parties can access a link to the live webcast of... |
| | | 05/02/12 | MannKind Corporation to Hold 2012 First Quarter Financial Results Conference Call on May 9, 2012| VALENCIA, Calif.--(BUSINESS WIRE)--May. 2, 2012--
MannKind Corporation (Nasdaq: MNKD) will release its 2012 first
quarter financial results on Wednesday, May 9, 2012 and its management
will host a conference call to discuss the first quarter financial
results and other Company developments at 5:00 PM (Eastern Time) on May
9, 2012.
Presenting from the Company will be its Chairman and Chief Executive
Officer, Alfred Mann, President and C... |
| | | 04/30/12 | Tolero and MannKind Sign Collaboration and License Agreement to Develop and Commercialize Novel BTK Inhibitors for Hematological Malignancies and Inflammatory Diseases| SALT LAKE CITY & VALENCIA, Calif.--(BUSINESS WIRE)--Apr. 30, 2012--
Tolero Pharmaceuticals, a biopharmaceutical company focused on the
discovery and development of novel therapeutics to treat cancer and
other serious human diseases, and MannKind Corporation (Nasdaq: MNKD),
focused on discovering, developing and commercializing therapeutic
products for diabetes and cancer, today announced a license agreement
granting Tolero exclusive worldwide rig... |
| | | 04/10/12 | MannKind to Present at Imperial Capital 2012 Healthcare Investor Forum| VALENCIA, Calif.--(BUSINESS WIRE)--Apr. 10, 2012--
MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing
and commercializing treatments for diabetes and cancer, announced today
that it will present at the Imperial Capital 2012 Healthcare Investor
Forum on Tuesday, April 17, 2012 at 9:00 am Eastern Time at the New York
Palace in New York.
Interested parties can access a link to the live webcast of the
presentations fro... |
| | | 02/29/12 | MannKind to Present at Cowen and Company 32nd Annual Health Care Conference| VALENCIA, Calif.--(BUSINESS WIRE)--Feb. 29, 2012--
MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing
and commercializing treatments for diabetes and cancer, announced today
that it will present at the Cowen and Company 32nd Annual Health Care
Conference on March 7, 2012 at 10:40am Eastern at the Boston Marriott
Copley Place in Boston, Massachusetts.
Interested parties can access a link to the live webcast of the
p... |
| | | 02/22/12 | MannKind Corporation Reports 2011 Fourth Quarter and Full Year Financial Results|
- Conference Call to Begin Today at 5:00 PM EST -
VALENCIA, Calif.--(BUSINESS WIRE)--Feb. 22, 2012--
MannKind Corporation (Nasdaq: MNKD) today reported financial
results for the fourth quarter and year ended December 31, 2011.
For the fourth quarter of 2011, total operating expenses were $30.6
million, compared to $32.1 million for the fourth quarter of 2010, a
decrease of $1.5 million. Research and development (R&D) expenses were... |
| | | 02/15/12 | MannKind Corporation to Hold 2011 Fourth Quarter and Full Year Financial Results Conference Call on February 22, 2012| VALENCIA, Calif.--(BUSINESS WIRE)--Feb. 15, 2012--
MannKind Corporation (Nasdaq: MNKD) will release its 2011 fourth
quarter and full year financial results on Wednesday, February 22, 2012
and its management will host a conference call to discuss the fourth
quarter and full year financial results and other Company developments
at 5:00 PM (Eastern Time) on February 22, 2012.
Presenting from the Company will be its Chairman and Chief Executive
... |
| | | 02/08/12 | MannKind Announces Exercise In Full of Over-Allotment Option and Completion of Public Offering of Units Consisting of Common Stock and Warrants to Purchase Common Stock| VALENCIA, Calif.--(BUSINESS WIRE)--Feb. 8, 2012--
MannKind Corporation (Nasdaq: MNKD) today announced the
completion of an underwritten public offering of 35,937,500 units,
including 4,687,500 units sold pursuant to the full exercise of an
over-allotment option previously granted to the underwriters (with each
unit consisting of one share of its common stock and a warrant to
purchase 0.6 of a share of its common stock). All of the securities were
... |
| | | 02/07/12 | MannKind to Present at Upcoming Conferences| VALENCIA, Calif.--(BUSINESS WIRE)--Feb. 7, 2012--
MannKind Corporation (Nasdaq: MNKD), focused on discovering,
developing and commercializing treatments for diabetes and cancer,
announced today that it will present at upcoming conferences.
The 14th Annual BioCEO Investor Conference on February 14,
2012 at 2:00 p.m. ET at the Waldorf-Astoria in New York, New York
The Leerink Swann 2012 Global Healthcare Conference... |
| | | 02/02/12 | MannKind Receives Commitment from The Mann Group to Acquire 31,250,000 Shares of Common Stock| VALENCIA, Calif.--(BUSINESS WIRE)--Feb. 2, 2012--
MannKind Corporation (Nasdaq: MNKD) today announced that it has
entered into a purchase agreement with The Mann Group LLC, an entity
controlled by MannKind’s chief executive officer and principal
stockholder, Alfred E. Mann, for the sale of shares of its common stock
to The Mann Group. The Mann Group has committed to purchase 31,250,000
restricted shares of MannKind’s common stock, the same number of ... |
| | | 02/02/12 | MannKind Announces Pricing of Public Offering of Units Consisting of Common Stock and Warrants to Purchase Common Stock| VALENCIA, Calif.--(BUSINESS WIRE)--Feb. 2, 2012--
MannKind Corporation (Nasdaq: MNKD) today announced the pricing
of an underwritten public offering of 31,250,000 units, with each unit
consisting of one share of its common stock and a warrant to purchase
0.6 of a share of its common stock. The shares of common stock and the
warrants are being offered at a combined price to the public of $2.40
per unit. The gross proceeds to MannKind from this offerin... |
| | | 01/31/12 | MannKind Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock| VALENCIA, Calif.--(BUSINESS WIRE)--Jan. 31, 2012--
MannKind Corporation (Nasdaq: MNKD) today announced that it
intends to offer and sell, subject to market and other conditions, $50
million worth of units in an underwritten public offering, with each
unit consisting of one share of MannKind’s common stock and a warrant to
purchase 0.6 of a share of MannKind’s common stock. MannKind also
intends to grant to the underwriters of the offering an option t... |
| | | 01/05/12 | MannKind to Present at 30th Annual J.P. Morgan Healthcare Conference| VALENCIA, Calif.--(BUSINESS WIRE)--Jan. 5, 2012--
MannKind Corporation (Nasdaq: MNKD), focused on discovering,
developing and commercializing treatments for diabetes and cancer,
announced today that it will present at the 30th Annual J.P. Morgan
Healthcare Conference on Thursday, January 12, 2012 at 8:00 am (PT) at
the Westin St. Francis Hotel in San Francisco, California.
Interested parties can access a link to the live webcast of the
... |
| |
|
